DK3141548T3 - Fremgangsmåder og mellemprodukter til fremstilling af azaindoler - Google Patents

Fremgangsmåder og mellemprodukter til fremstilling af azaindoler Download PDF

Info

Publication number: DK3141548T3
Authority: DK; Denmark
Prior art keywords: azaindoles; intermediates; preparation; methods
Prior art date: 2011-07-05

Application number

DK16190960.1T

Other languages

English (en)

Inventor

Gerald J Tanoury

Young Chun Jung

Derek Magdziak

Adam Looker

Billie J Kline

Olmo Beatriz Dominguez

Václav Jurcík

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-05

Filing date

2012-07-03

Publication date

2020-07-06

2012-07-03 Application filed by Vertex Pharma filed Critical Vertex Pharma

2020-07-06 Application granted granted Critical

2020-07-06 Publication of DK3141548T3 publication Critical patent/DK3141548T3/da

Links

125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 title 1
239000000543 intermediate Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Steroid Compounds (AREA)

DK16190960.1T 2011-07-05 2012-07-03 Fremgangsmåder og mellemprodukter til fremstilling af azaindoler DK3141548T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161504351P	2011-07-05	2011-07-05
US201261636296P	2012-04-20	2012-04-20
EP12735411.6A EP2729465A2 (en)	2011-07-05	2012-07-03	Processes and intermediates for producing azaindoles

Publications (1)

Publication Number	Publication Date
DK3141548T3 true DK3141548T3 (da)	2020-07-06

Family

ID=46513874

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16190960.1T DK3141548T3 (da)	2011-07-05	2012-07-03	Fremgangsmåder og mellemprodukter til fremstilling af azaindoler

Country Status (19)

Country	Link
US (5)	US8513414B2 (da)
EP (2)	EP2729465A2 (da)
JP (3)	JP2014520815A (da)
KR (1)	KR20140058547A (da)
CN (2)	CN106432311A (da)
AR (1)	AR087069A1 (da)
AU (1)	AU2012279046B2 (da)
BR (1)	BR112014000115A2 (da)
CA (1)	CA2839937C (da)
DK (1)	DK3141548T3 (da)
ES (1)	ES2804528T3 (da)
MX (1)	MX2013015147A (da)
NZ (2)	NZ619699A (da)
PL (1)	PL3141548T3 (da)
PT (1)	PT3141548T (da)
RU (1)	RU2014103806A (da)
TW (1)	TW201321378A (da)
WO (1)	WO2013006634A2 (da)
ZA (1)	ZA201400049B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2311837B1 (en) *	2004-03-30	2014-05-21	Vertex Pharmaceuticals Inc.	Azaindoles useful as inhibitors of jak and other protein kinases
NZ597059A (en)	2009-06-17	2014-01-31	Vertex Pharma	Inhibitors of influenza viruses replication
CA2839937C (en)	2011-07-05	2020-11-03	Vertex Pharmaceuticals Incorporated	Processes and intermediates for producing azaindoles
UA118010C2 (uk)	2011-08-01	2018-11-12	Вертекс Фармасьютікалз Інкорпорейтед	Інгібітори реплікації вірусів грипу
WO2014201332A1 (en)	2013-06-14	2014-12-18	Vertex Pharmaceuticals Incorporated	Pharmaceutical combinations useful for treating rheumatoid arthritis
EP3036225A1 (en)	2013-08-22	2016-06-29	Vertex Pharmaceuticals Incorporated	Isotopically enriched azaindoles
US9296727B2 (en)	2013-10-07	2016-03-29	Vertex Pharmaceuticals Incorporated	Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
HUE052178T2 (hu) *	2013-11-13	2021-04-28	Vertex Pharma	Eljárások influenzavírus-replikáció inhibitorainak elõállítására
SG10201804026WA (en)	2013-11-13	2018-06-28	Vertex Pharma	Inhibitors of influenza viruses replication
WO2016183116A1 (en)	2015-05-13	2016-11-17	Vertex Pharmaceuticals Incorporated	Methods of preparing inhibitors of influenza viruses replication
MA42422A (fr)	2015-05-13	2018-05-23	Vertex Pharma	Inhibiteurs de la réplication des virus de la grippe
RU2737190C2 (ru) *	2015-12-09	2020-11-25	Саншайн Лейк Фарма Ко., Лтд.	Ингибиторы репликации вируса гриппа, способы их применения и использование
CN105523986A (zh) *	2015-12-30	2016-04-27	江汉大学	一种外排泵抑制剂n-氢-2-芳基吲哚及其衍生物的合成方法
SI3510031T1 (sl) *	2016-09-09	2021-03-31	F. Hoffmann-La Roche Ag	Postopek za pripravo 2-(6-nitropiridin-3-il)-9H-dipirido(2,3-b;3',4'-d)pirola
EP4183786A1 (en)	2016-12-23	2023-05-24	Felicitex Therapeutics, Inc.	Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases
JP2022515272A (ja) *	2018-12-24	2022-02-17	チアタイティエンチンファーマシューティカルグループカンパニーリミテッド	ピロロピリミジン化合物の治療的使用およびその固形医薬組成物
CN113121452A (zh) *	2021-05-10	2021-07-16	甘肃堡昌化工有限公司	一种硫酸法尿嘧啶的精制工艺
CN113851244A (zh) *	2021-09-18	2021-12-28	浙江爱索拓科技有限公司	一种含放射性同位素碳-14废水的处理方法
CN113896716A (zh) *	2021-10-27	2022-01-07	浙江爱索拓科技有限公司	一种放射性同位素碳-14双标记甲磺酸伏美替尼合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9721437D0 (en)	1997-10-10	1997-12-10	Glaxo Group Ltd	Heteroaromatic compounds and their use in medicine
US20020065270A1 (en)	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
AU3704101A (en)	2000-02-17	2001-08-27	Amgen Inc	Kinase inhibitors
UY26942A1 (es) *	2000-09-20	2002-04-26	Abbott Lab	N-acilsulfonamidas promotoras de la apoptosis
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
EP1506189A1 (en)	2002-04-26	2005-02-16	Vertex Pharmaceuticals Incorporated	Pyrrole derivatives as inhibitors of erk2 and uses thereof
CN1656079A (zh)	2002-05-31	2005-08-17	卫材株式会社	吡唑化合物和含有该化合物的药物组合物
EP1675830A4 (en) *	2003-09-30	2008-08-20	Scios Inc	HETEROCYCLIC AMIDES AND SULFONAMIDES
JP4605606B2 (ja)	2004-01-30	2011-01-05	長瀬産業株式会社	軸不斉を有する光学活性な４級アンモニウム塩およびそれを用いたα−アミノ酸およびその誘導体の製造方法
EP2311837B1 (en)	2004-03-30	2014-05-21	Vertex Pharmaceuticals Inc.	Azaindoles useful as inhibitors of jak and other protein kinases
UA87494C2 (en) *	2004-03-30	2009-07-27	Вертекс Фармасьютикалс Инкорпорейтед	Azaindoles useful as inhibitors of jak and other protein kinases
WO2006038001A1 (en) *	2004-10-06	2006-04-13	Celltech R & D Limited	Aminopyrimidine derivatives as jnk inhibitors
RU2435769C2 (ru)	2005-05-20	2011-12-10	Вертекс Фармасьютикалз Инкорпорейтед	Пирролопиридины, полезные в качестве ингибиторов протеинкиназы
JP5591471B2 (ja)	2006-01-17	2014-09-17	バーテックスファーマシューティカルズインコーポレイテッド	ヤヌスキナーゼ阻害剤として有用なアザインドール
CN101374839A (zh) *	2006-01-17	2009-02-25	沃泰克斯药物股份有限公司	适用作詹纳斯激酶抑制剂的吖吲哚类
ES2431466T3 (es) *	2006-06-30	2013-11-26	Sunesis Pharmaceuticals, Inc.	Inhibidores de piridinonil pdk1
JP4450857B2 (ja) *	2006-08-08	2010-04-14	中外製薬株式会社	Ｐｉ３ｋ阻害剤としてのピリミジン誘導体およびその用途
MX2009006345A (es)	2006-12-14	2009-06-23	Vertex Pharma	Compuestos utiles como inhibidores de proteina cinasa.
CA2704633C (en) *	2007-11-05	2015-10-20	Novartis Ag	4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
ATE522535T1 (de) *	2008-02-25	2011-09-15	Hoffmann La Roche	Pyrrolotriazin-kinasehemmer
NZ597059A (en)	2009-06-17	2014-01-31	Vertex Pharma	Inhibitors of influenza viruses replication
CA2839937C (en)	2011-07-05	2020-11-03	Vertex Pharmaceuticals Incorporated	Processes and intermediates for producing azaindoles
UA118010C2 (uk)	2011-08-01	2018-11-12	Вертекс Фармасьютікалз Інкорпорейтед	Інгібітори реплікації вірусів грипу
EP2776036A1 (en)	2011-11-07	2014-09-17	Vertex Pharmaceuticals Incorporated	Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor
EP3036225A1 (en)	2013-08-22	2016-06-29	Vertex Pharmaceuticals Incorporated	Isotopically enriched azaindoles

2012
- 2012-07-03 CA CA2839937A patent/CA2839937C/en active Active
- 2012-07-03 NZ NZ619699A patent/NZ619699A/en not_active IP Right Cessation
- 2012-07-03 CN CN201610811795.3A patent/CN106432311A/zh active Pending
- 2012-07-03 EP EP12735411.6A patent/EP2729465A2/en not_active Withdrawn
- 2012-07-03 US US13/541,504 patent/US8513414B2/en not_active Expired - Fee Related
- 2012-07-03 ES ES16190960T patent/ES2804528T3/es active Active
- 2012-07-03 MX MX2013015147A patent/MX2013015147A/es not_active Application Discontinuation
- 2012-07-03 NZ NZ714502A patent/NZ714502A/en not_active IP Right Cessation
- 2012-07-03 JP JP2014519264A patent/JP2014520815A/ja not_active Withdrawn
- 2012-07-03 BR BR112014000115A patent/BR112014000115A2/pt not_active IP Right Cessation
- 2012-07-03 RU RU2014103806/04A patent/RU2014103806A/ru not_active Application Discontinuation
- 2012-07-03 PL PL16190960T patent/PL3141548T3/pl unknown
- 2012-07-03 DK DK16190960.1T patent/DK3141548T3/da active
- 2012-07-03 WO PCT/US2012/045431 patent/WO2013006634A2/en not_active Ceased
- 2012-07-03 PT PT161909601T patent/PT3141548T/pt unknown
- 2012-07-03 AU AU2012279046A patent/AU2012279046B2/en not_active Ceased
- 2012-07-03 EP EP16190960.1A patent/EP3141548B9/en active Active
- 2012-07-03 KR KR1020147003091A patent/KR20140058547A/ko not_active Withdrawn
- 2012-07-03 CN CN201280036682.0A patent/CN103702998A/zh active Pending
- 2012-07-04 TW TW101124076A patent/TW201321378A/zh unknown
- 2012-07-05 AR ARP120102438A patent/AR087069A1/es unknown
2013
- 2013-07-12 US US13/940,421 patent/US8796453B2/en not_active Expired - Fee Related
2014
- 2014-01-06 ZA ZA2014/00049A patent/ZA201400049B/en unknown
- 2014-06-25 US US14/314,158 patent/US8946425B2/en active Active
- 2014-12-15 US US14/570,044 patent/US9090614B2/en not_active Expired - Fee Related
2015
- 2015-06-17 US US14/741,499 patent/US20150284388A1/en not_active Abandoned
2016
- 2016-07-22 JP JP2016144361A patent/JP2017002067A/ja not_active Withdrawn
2018
- 2018-07-19 JP JP2018135847A patent/JP6761448B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20150099884A1 (en)	2015-04-09
ES2804528T3 (es)	2021-02-08
RU2014103806A (ru)	2015-08-10
NZ714502A (en)	2017-04-28
US9090614B2 (en)	2015-07-28
EP3141548B9 (en)	2020-08-12
AU2012279046A1 (en)	2014-01-23
CN103702998A (zh)	2014-04-02
JP2014520815A (ja)	2014-08-25
US20150284388A1 (en)	2015-10-08
US20140309421A1 (en)	2014-10-16
WO2013006634A2 (en)	2013-01-10
US8796453B2 (en)	2014-08-05
JP2018162314A (ja)	2018-10-18
JP6761448B2 (ja)	2020-09-23
BR112014000115A2 (pt)	2016-10-04
US20130102782A1 (en)	2013-04-25
AU2012279046B2 (en)	2017-08-31
MX2013015147A (es)	2014-03-27
CN106432311A (zh)	2017-02-22
EP2729465A2 (en)	2014-05-14
US20130303764A1 (en)	2013-11-14
CA2839937C (en)	2020-11-03
US8513414B2 (en)	2013-08-20
US8946425B2 (en)	2015-02-03
PT3141548T (pt)	2020-07-10
CA2839937A1 (en)	2013-01-10
ZA201400049B (en)	2015-04-29
EP3141548A1 (en)	2017-03-15
JP2017002067A (ja)	2017-01-05
WO2013006634A3 (en)	2013-05-10
EP3141548B1 (en)	2020-04-08
NZ619699A (en)	2016-03-31
PL3141548T3 (pl)	2020-09-07
WO2013006634A9 (en)	2013-03-21
KR20140058547A (ko)	2014-05-14
TW201321378A (zh)	2013-06-01
AR087069A1 (es)	2014-02-12

Publication	Publication Date	Title
DK3141548T3 (da)	2020-07-06	Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
DK3238709T3 (da)	2020-09-28	Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
DK2739293T3 (da)	2020-08-24	Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK2914627T3 (da)	2021-07-12	Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK2768524T3 (da)	2022-07-04	PD-L1-baseret immunterapi
DK2553113T3 (da)	2022-01-24	FREMGANGSMÅDE TIL FREMSTILLING AF L-ORNITHIN UNDER ANVENDELSE AF LysE-OVEREKSPRIMERENDE BAKTERIER
CO6821892A2 (es)	2013-12-31	Anticuerpos anti-angptl3 y usos de los mismos
DK3556774T3 (da)	2024-03-25	Anti-CD40-antistoffer og anvendelser deraf
DK2675827T3 (da)	2020-09-07	Hidtil ukendte modulatorer og fremgangsmåder til anvendelse
HRP20180571T1 (hr)	2018-05-18	Polipeptidiantitijela koji antagoniziraju cd40
DK2766392T3 (da)	2019-10-07	Fremgangsmåde til oprensning af antistoffer
DK2683731T3 (da)	2019-06-11	C4-monomethyl-triterpenoidderivater og fremgangsmåder til anvendelse deraf
HUE052485T2 (hu)	2021-05-28	RNA készítmény immunterápiára
DK2768321T3 (da)	2020-08-31	Fremgangsmåder og sammensætninger til induktion af mæthed
HUE037048T2 (hu)	2018-08-28	Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
DK2718404T3 (da)	2021-04-26	Fremgangsmåde til fremstilling af flydende carbonhydrider
CO6960555A2 (es)	2014-05-30	Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
DK2785801T4 (da)	2019-10-07	Fremgangsmåde til formindskelse af isdannelse på et underlag
DK3656758T3 (da)	2024-04-22	Mellemprodukter til fremstilling af c-terminale hsp90-inhibitorer
DK3050883T3 (da)	2020-05-25	Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
DK2627656T3 (da)	2014-09-08	Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
BR112013025299A2 (pt)	2016-12-13	conjunto de ancoragem
DK2771022T3 (da)	2020-09-28	Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf
DK2661274T3 (da)	2019-08-26	Sammensætninger og fremgangsmåder med aloepolysaccharider
EP2714694A4 (en)	2014-11-05	BAKTERIOCHLORIMIDE